Gyre Therapeutics (Gyre Therapeutics) EBITDA Margin % : 17.92% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gyre Therapeutics's EBITDA for the six months ended in Dec. 2023 was $20.3 Mil. Gyre Therapeutics's Revenue for the six months ended in Dec. 2023 was $113.5 Mil. Therefore, Gyre Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was 17.92%.

Gyre Therapeutics EBITDA Margin % Historical Data

The historical data trend for Gyre Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics EBITDA Margin % Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

35.33

10.10

17.92

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
EBITDA Margin %	35.33	10.10	17.92

Competitive Comparison of Gyre Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Gyre Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's EBITDA Margin % falls into.

Gyre Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Gyre Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	20.327	/	113.45
	=	17.92 %

Gyre Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	20.327	/	113.45
	=	17.92 %

Gyre Therapeutics (NAS:GYRE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Gyre Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023